Last Intermediate Review Completed for Celsion Corp. (CLSN) Phase III HEAT Study of ThermoDox for Treating Primary Liver Cancer
Leading oncology drug development company Celsion Corporation has announced that the independent Data Monitoring Committee (DMC) for its HEAT Study has completed a regularly scheduled review of the 701 patients enrolled in the trial and unanimously recommends that the HEAT Study continue according to protocol to its final data readout. The HEAT Study, being conducted under a Special Protocol Assessment (SPA) agreed to with the FDA, is a fully enrolled, multinational, double-blind, placebo-controlled Phase III trial of ThermoDox in combination with radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC or primary liver cancer). Progression-free survival (PFS), the HEAT Study’s primary endpoint,…